<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="75418">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01741844</url>
  </required_header>
  <id_info>
    <org_study_id>CR100806</org_study_id>
    <secondary_id>TMC125HIV4017</secondary_id>
    <secondary_id>Intelene PMS</secondary_id>
    <secondary_id>ETR-C-11-KR-001-V04</secondary_id>
    <nct_id>NCT01741844</nct_id>
  </id_info>
  <brief_title>A Post Marketing Survey Study to Evaluate the Safety and Effectiveness of Intelence</brief_title>
  <official_title>Regulatory Post Marketing Surveillance of Intelence Tablet</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Korea, Ltd., Korea</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Korea, Ltd., Korea</source>
  <oversight_info>
    <authority>Korea: Food and Drug Administration</authority>
    <authority>Republic of Korea: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety data of etravirine in a natural clinical
      practice.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a non-interventional (a scientific study to make a clear and easy understanding of
      the cause and effect relationship), prospective (in which the participants are first
      identified and then followed forward as time passes), consecutive survey for collecting
      safety and efficacy data of etravirine in treatment of Acquired Immune Deficiency Syndrome
      (AIDS) in a natural clinical practice.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case-Only, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>Up to 30 days from end of treatment</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with viral load</measure>
    <time_frame>Screening, Week 12, Week 24</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with CD4 T-cell count</measure>
    <time_frame>Screening, Week 12, Week 24</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">3000</enrollment>
  <condition>Acquired Immune Deficiency Syndrome</condition>
  <arm_group>
    <arm_group_label>Etravirine</arm_group_label>
    <description>Patients having Acquired Immune Deficiency Syndrome (AIDS) will be taking etravirine as per recommended doses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <description>This is an observational study. Etravirine 200 mg will be adminstered twice daily in patients with Acquired Immune Deficiency Syndrome (AIDS).</description>
    <arm_group_label>Etravirine</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study population will include patients who are diagnosed with Acquired Immune
        Deficiency Syndrome (AIDS), and who are prescribed with etravirine for treatment of AIDS.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who are prescribed with etravirine for treatment of Acquired Immune
             Deficiency Syndrome (AIDS)

        Exclusion Criteria:

          -  Known hypersensitivity to Intelence

          -  Intelence coadministered with medicinal products that are highly dependent on CYP3A
             and CYP2C9 for clearance

          -  Patients with galactose intoralance, Lapp lactase deficiency, and glucose-galactose
             malabsorption
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Korea, Ltd., Korea Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Korea, Ltd., Korea</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Dae-Gu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 12, 2014</lastchanged_date>
  <firstreceived_date>December 3, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acquired Immune Deficiency Syndrome</keyword>
  <keyword>TMC125</keyword>
  <keyword>Etravirine</keyword>
  <keyword>Intelence</keyword>
  <keyword>AIDS</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
